| |
Resistance pattern
|
---|
Total no. of isolates
| |
NAL
|
CIP
|
MDRa
|
---|
|
Year
|
no. (%)
|
no. (%)
|
no. (%)
|
---|
10
|
2002
|
2 (20)
|
0 (0)
|
0 (0)
|
16
|
2003
|
6 (37.5)
|
0 (0)
|
2 (12.5)
|
13
|
2004
|
5 (38.5)
|
1 (7.7)
|
2 (15.4)
|
16
|
2005
|
5 (31.3)
|
3 (18.8)
|
1 (6.3)
|
16
|
2006
|
9 (56.3)
|
3 (18.8)
|
0 (0)
|
18
|
2007
|
15 (83.3)
|
5 (27.8)
|
3 (16.7)
|
16
|
2008
|
9 (56.3)
|
3 (18.8)
|
3 (18.8)
|
18
|
2009
|
14 (77.8)
|
1 (5.6)
|
1 (5.6)
|
24
|
2010
|
20 (83.3)
|
6 (25)
|
4 (16.7)
|
15
|
2011
|
9 (60)
|
4 (26.7)
|
3 (20)
|
12
|
2012
|
7 (58.3)
|
3 (25)
|
3 (25)
|
18
|
2013
|
12 (66.7)
|
10 (55.6)
|
0 (0)
|
Total
| | | | |
192
| |
113 (58.9)
|
39 (20.3)
|
22 (11.5)
|
- Abbreviations: NAL, nalidixic acid; CIP, ciprofloxacin; MDR, multidrug resistant
- aMultidrug resistance is defined as resistance to ampicillin, trimethoprim/sulfamethoxazole and chloramphenicol (13)